Novartis snaps up cancer drug developer Endocyte for $2.1 billion

pharmafile | October 18, 2018 | News story | Research and Development, Sales and Marketing Cancer, Endocyte, Novartis, pharma 

Novartis will shell out $2.1 billion to acquire cancer drug developer Endocyte in a move to leverage the company’s technology to investigate potential development of therapies in prostate cancer, it has emerged.

The deal will see Novartis acquire all of Endocyte’s outstanding shares of common stock for $24 per share, equating to the valuation of $2.1 billion, and will allow the pharma giant to take advantage of the latter’s drug conjugation technology to develop therapies with companion imaging agents.

Among the drug candidates developed through the technology is Lu-PSMA-617, a radioligand therapy (RLT) aimed at the treatment of metastatic castration-resistant prostate cancer (mCRPC). The therapy has shown promise in Phase 2 trials, demonstrating a median prostate specific antigen (PSA) progression free survival (PFS) of 7.6 months in the treatment of mCRPC, as well as a median overall survival of 13.5 months. Endocyte is currently enrolling patients for a Phase 3 study of the candidate.

Through the acquisition of Endocyte, Novartis hopes to further investigate Lu-PSMA-617 for use in earlier lines of prostate cancer therapy, as well as expand its existing RLT platform with “potential near-term product launch and early-stage clinical development programmes”.

“Novartis has a strong legacy of addressing unmet needs with transformative therapies and is building a leadership capability in new, technology-driven platforms that address some of the world’s most complex health challenges, including cancer,” commented Liz Barrett, CEO of Novartis Oncology.  “Today’s announcement about the proposed acquisition of Endocyte builds on our growing capability in radiopharmaceuticals, which is expected to be an increasingly important treatment option for patients and a key growth driver for our business. We are also excited about the opportunity to break into the prostate cancer arena with a near-term product that has the potential to make a meaningful impact for patients in great need of more options.”

Matt Fellows

Related Content


AstraZeneca shares oncology data at ASCO 2023

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …

AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy

AstraZeneca has announced positive results from the FLAURA2 phase 3 trial which showed that Tagrisso …

Thermo Fisher and Pfizer collaborate on NGS-based cancer tests

Scientific equipment provider Thermo Fisher and US pharmaceutical firm Pfizer have announced a collaboration to …

Latest content